The study showed that in the patients with diabetes who had worsening heart failure, the total number of cardiovascular deaths, hospitalizations, and urgent visits for HF was significantly lower with the SGLT2 and SGLT1 inhibitor sotagliflozin than with placebo. This evidence concerns the gene SLC5A2 and diabetes mellitus.